GT Biopharma Inc (GTBP)

[MagnumStocks]

$GTBP Exec Team Stacked with Superstars. The progress of recent months $GTBP has made in enhancing their executive team is a very important indicator for investors. The kind of leadership that has signed on board is the kind that has already guided developmental stage bioscience companies to MASSIVE profitability. The fact that they see similar potential in $GTBP is very telling. Because of the laws and SEC regulations surrounding forward looking statements, a developmental stage company like this can't come out and say "Hey, We really have a winning offering, and we are about to make boatloads of money." As investors we wish it could be that straightforward so we could have a clear BUY sign, but it just doesn't work that way. We have to look for other, less-direct signals, like the one we have here.

You have a bunch of succesful, already wealthy, extremely qualified executives, who collectively have seen several bioscience companies grow through to the multibillion dollar exit strategy stage, who have recently signed on with GTBP which has promising drugs in the pipeline on the verge of clinical testing validation. Do your think executives of that calibre are just looking for some place to park? Or does their years of experience in biopharma tell them something about $GTBP that we ought to stop and take notice of?

Management and Board Enhancement

2017 was a critical year in enhancing our management team and we made considerable progress in this regard.

On September 1, 2017, our Chief Executive Officer, Dr. Kathleen Clarence-Smith M.D., P.H.D. joined the company and brought substantial clinical development and intellectual property expertise (co-founder Chase Pharmaceuticals; formerly with Sanofi and Roche). We were also able to attract and hire Dr. Raymond Urbanski M.D., P.H.D. as Chief Medical Officer (a clinical oncologist formerly with Pfizer and Mylan). In November of 2017, Shawn Cross (formerly of Deutsche Bank) joined as President and Chief Operating Officer to help drive our strategy, interact with potential large pharmaceutical partners, and enhance our visibility with Wall Street. Finally, we announced Geoff Davis joined our board on January 16, 2018. Geoff is a former partner at Ropes & Gray where he played a significant role in establishing the firm's internationally-recognized Life Sciences Group. His over 25 years of work includes numerous partnering and licensing transactions for major pharmaceutical companies, as well as for public and private biotechnology companies. Each is a welcome addition to our team.